Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1995 Sep;233(9):559-62.
doi: 10.1007/BF00404706.

The effect of argon laser trabeculoplasty on the blood-aqueous barrier and intraocular pressure in human glaucomatous eyes treated with diclofenac 0.1%

Clinical Trial

The effect of argon laser trabeculoplasty on the blood-aqueous barrier and intraocular pressure in human glaucomatous eyes treated with diclofenac 0.1%

M Diestelhorst et al. Graefes Arch Clin Exp Ophthalmol. 1995 Sep.

Abstract

Background: We studied the effect of argon laser trabeculoplasty (ALT) on the blood-aqueous barrier (BAB) in 41 eyes of 41 patients with primary open-angle glaucoma, pseudoexfoliation glaucoma, or pigment dispersion glaucoma using the Fluorotron Master II.

Methods: Fluorophotometry was performed the day before ALT and on the 3rd day after surgery at 30 and 60 min after intravenous injection of 7 mg/kg body weight sodium fluorescein 10%. Intraocular pressure (IOP) was measured using Goldmann applanation tonometry on the day before surgery and at 3rd days and 1 year (mean) after ALT. Patients were treated with argon laser by one surgeon (180 degrees, 0.1 s, 50 microns 0.6-1.0 W, 56 laser burns). Eyes were randomly assigned to either diclofenac-sodium 0.1% eye drops or vehicle. Eye drops were applied six times 1 h before ALT into the operated eyes and five times daily for 3 days postoperatively.

Results: On the 3rd day after ALT there was significant disruption of the BAB in the placebo-treated eyes compared to the diclofenac 0.1%-treated eyes. In the placebo-treated eyes as well as in diclofenac-sodium 0.1%-treated eyes there was a significant decrease of IOP postoperatively for up to 1 year. There was no significant difference concerning the IOP reduction after 1 year. Diclofenac-sodium 0.1% eye drops significantly stabilized the BAB on the 3rd day after ALT, compared to placebo, in this model.

Conclusion: Diclofenac-sodium 0.1% significantly stabilized the disruption of the blood-aqueous barrier on the 3rd day after ALT. Concerning the IOP-lowering effect of ALT, the postoperative application of steroids should be avoided.

PubMed Disclaimer

References

    1. Am J Ophthalmol. 1985 Apr 15;99(4):388-91 - PubMed
    1. Am J Ophthalmol. 1983 Aug;96(2):139-47 - PubMed
    1. Graefes Arch Clin Exp Ophthalmol. 1985;222(4-5):190-3 - PubMed
    1. Ophthalmic Surg. 1992 Sep;23(9):614-7 - PubMed
    1. Invest Ophthalmol Vis Sci. 1982 Jan;22(1):45-56 - PubMed

Publication types

Substances

LinkOut - more resources